Navigation Links
Amarin Announces Financial Results for Fourth Quarter and Full Year 2007
Date:5/19/2008

y Share

consolidation.

4. Non-current assets - Intangible assets

Intangible assets of $19,916,000 relate to the acquisition of Ester

Neurosciences Limited on December 5, 2007 representing the upfront

acquisition consideration already satisfied in cash and shares in

December 2007 plus $4,756,000 of a provision relating to a future

contingent milestone, likely payable during 2008. This milestone is

payable in cash or shares, at Amarin's option (see note 6 below).

5. Non-current liabilities - Convertible debt

In December 2007, the company issued $2.75 million 8% convertible notes.

These notes are being repaid out of the proceeds of the first tranche of

the funding announced on May 14, 2008.The difference between the carrying

amount of the liability component at the date of issue and the amount

reported in the balance sheet at December 31, 2007 represents the change

in amortized cost under the effective interest rate method.

6. Current liabilities - Provisions

Included in provisions is $4,756,000 which relates to the fair value of

the contingent consideration payable to former Ester shareholders in cash

or shares, at Amarin's option, on the achievement of a certain milestone

as a result of the acquisition of Ester Neurosciences Limited on December

5, 2007. The achievement of this milestone is considered to be probable

and is recognized as a liability.

7. Basis of preparation

As at December 31, 2007, the Company had cash balances of $18,303,000.

As previously announced, on May 14, 2008, Amarin announced a private

placement of ordinary shares for up to $60 million to be funded in two

equal tranches. Amarin expects to announce the closing of the first

tranche shortly. The investors in this funding have an option to fund up

to $30 million in the second tranche upon completion of certain business


'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amarin Secures Global Intellectual Property Rights for Lipid Programs
2. Amarin Appoints Dr. William Mason as Lead Independent Director
3. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
4. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
5. Amarin Signs Agreement to Acquire Ester Neurosciences
6. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
7. Amarin Announces Initiation of Cardiovascular Development Strategy
8. Amarin to Present at 4th Annual Bio Investor Forum
9. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
10. Volcano Announces Acquisition of Novelis, Inc.
11. RainDance Announces Company Relocation and Manufacturing Startup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
(Date:8/28/2014)... Ca. (PRWEB) August 28, 2014 Best ... rating for an alcohol-based hand sanitizer, asks food processors ... by comparing the hand sanitizer they’re currently using to ... . Hand hygiene is critical to fighting cross-contamination and ... Best Sanitizers believes there are key criteria that ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... new market research report is ... Whole Exome Sequencing Market ... Preparation, Target Enrichment), by Services ... Synthesis), by Application (Cancer, Monogenic ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... researchers at the Swedish medical university Karolinska Institutet shows ... "bad" LDL cholesterol and thereby cause an inflammation that ... T cell receptors, the researchers have managed to inhibit ... presented online in the distinguished periodical Journal of ...
... discovered that simple peptides can organize into bi-layer membranes. ... pre-biotic Earth,s chemical inventory and the organizational scaffolding essential ... form the kind of membranes needed to create long-range ... of the paper recently published by the German Chemical ...
... Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA , and VANCOUVER , May 6 /PRNewswire-FirstCall/ - OncoGenex ... three months ended March 31, 2010 and reviewed the Company,s highlights for the first quarter ... Financial Results , , , ...
Cached Biology Technology:New atherosclerosis vaccine gives promising results 2Peptides may hold 'missing link' to life 2Peptides may hold 'missing link' to life 3OncoGenex Reports First Quarter Financial Results 2OncoGenex Reports First Quarter Financial Results 3OncoGenex Reports First Quarter Financial Results 4OncoGenex Reports First Quarter Financial Results 5OncoGenex Reports First Quarter Financial Results 6OncoGenex Reports First Quarter Financial Results 7OncoGenex Reports First Quarter Financial Results 8OncoGenex Reports First Quarter Financial Results 9
(Date:8/28/2014)... PAUL (August 28, 2014) Researchers at the University ... facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle ... of potential therapies for FSHD. , The research is ... Cell Reports . , There is no treatment for ... most common type of muscular dystrophy. FSHD is an ...
(Date:8/28/2014)... that could positively impact the global battle ... thanks to researchers in Penn State,s College ... made from the seaweed-derived food ingredient carrageenan ... provides a woman-initiated, drug-delivery vehicle that can ... infections during unprotected heterosexual intercourse, the researchers ...
(Date:8/28/2014)... 25 million kilometres of new roads will be built ... into Earth,s last wildernesses, where they bring an influx ... Now, an ambitious study has created a ,global roadmap, ... to balance the competing demands of development and environmental ... layer that estimates that natural importance of ecosystems and ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... the European Medicines Agency (EMA) approved the modified adeno-associated ... for clinical use in the Western world. uniQure, a ... treatment of a rare inherited metabolic disease called lipoprotein ... out of one million people. The disease causes severe, ...
... 2013  Paris Air Show – Marvin Test Solutions ... provider of innovative test solutions for military and commercial ... the Paris Air Show in booth 3-C82. ... longer lifecycles, industry leaders are demanding efficient, feature-rich, specialized ...
... Kingdom, the Energy Department,s National Renewable Energy Laboratory (NREL), ... paper describing a novel cellulose-degrading enzyme from a marine ... the gribble. Gribbles are biologically intriguing because ... own enzymes instead of using symbiotic microbes to break ...
Cached Biology News:No danger of cancer through gene therapy virus 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Novel enzyme from tiny gribble could prove a boon for biofuels research 2
...
... Human IgG Fd. ELISA Specificity: (4) ,human IgG subclass 1 ... 100% ,human IgG subclass 3 100% ,human IgG ... ... 0.04% ,human IgG Fab ...
Human VEGF R2 (KDR) MAb (Clone 89106)...
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
Biology Products: